---
title: "MOLN: MP0712 advances in SCLC trials, CD70 program announced, and cash runway extends into late 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296873375.md"
description: "Advanced clinical pipeline with MP0712 progressing in SCLC and new CD70 program for kidney cancer. Cash position of CHF 67.9 million expected to fund operations into late 2027, with improved operating loss and continued focus on targeted cancer therapies.Original document: Molecular Partners AG [MOLN] SEC 6-K Current Report — Aug. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-25T07:21:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296873375.md)
  - [en](https://longbridge.com/en/news/296873375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296873375.md)
generator: "portal-rs"
---

# MOLN: MP0712 advances in SCLC trials, CD70 program announced, and cash runway extends into late 2027

Advanced clinical pipeline with MP0712 progressing in SCLC and new CD70 program for kidney cancer. Cash position of CHF 67.9 million expected to fund operations into late 2027, with improved operating loss and continued focus on targeted cancer therapies.

Original document: Molecular Partners AG \[MOLN\] SEC 6-K Current Report — Aug. 25 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MOLN.US](https://longbridge.com/en/quote/MOLN.US.md)

## Related News & Research

- [MOLN: Cash of CHF 68M supports advancing DARPin oncology pipeline, with key data expected in 2026](https://longbridge.com/en/news/296862063.md)
- [Molecular Partners GAAP EPS of -CHF0.70](https://longbridge.com/en/news/296910213.md)
- [HAMLET.B: Advanced cancer and infection therapies reached Phase III, supported by strong R&D and financing](https://longbridge.com/en/news/297278926.md)
- [AI turns up a promising finding in cancer data that researchers hadn’t noticed for years](https://longbridge.com/en/news/297215988.md)
- [Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating](https://longbridge.com/en/news/296952976.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**